Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Telephone monitoring of adverse events during an MF59®-adjuvanted H5N1 influenza vaccination campaign in Taiwan.

Huang WT, Chang CH, Peng MC.

Hum Vaccin Immunother. 2014;10(1):100-3. doi: 10.4161/hv.26737.


A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R.

Hum Vaccin Immunother. 2014;10(1):92-9. doi: 10.4161/hv.26495.


Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR; National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units..

JAMA. 2014 Oct 8;312(14):1420-8. doi: 10.1001/jama.2014.12609.


Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.

Clin Vaccine Immunol. 2012 Dec;19(12):1943-8. doi: 10.1128/CVI.00373-12.


Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019.


AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW.

J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548.


Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.


Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053.


Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

Hwang SM, Kim HL, Min KW, Kim M, Lim JS, Choi JM, Chun BC, Kim MJ, Lee SM, Kim SY, Jeon HH.

Jpn J Infect Dis. 2012;65(3):193-7.


Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628.


A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.

Moro ML, Nobilio L, Voci C, Di Mario S, Candela S, Magrini N; SaFoH1N1 working group..

Vaccine. 2013 Feb 27;31(10):1438-46. doi: 10.1016/j.vaccine.2012.07.090.


Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.

Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, Chen Z.

Arch Virol. 2011 Mar;156(3):387-95. doi: 10.1007/s00705-010-0860-4.


Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.

Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R.

Hum Vaccin Immunother. 2012 Jul;8(7):921-8. doi: 10.4161/hv.20248.


The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.

Wei SH, Liu MT, Tsai YC, Liao CH, Chen CM, Wang WY, Huang YL, Chang FY, Chou P.

BMC Infect Dis. 2014 Nov 14;14:587. doi: 10.1186/s12879-014-0587-z.


A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.

Czajka H, Unal S, Ulusoy S, Usluer G, Strus A, Sennaroglu E, Guzik J, Topeli Iskit A, Dargiewicz A, Musial D, Caylan R, Dziduch J, Eskioglu E, Hasiec B, Cwinarowiczliwa E, Belli R, Abdel-Messih IA, Beygo J, Fragapane E.

J Prev Med Hyg. 2012 Sep;53(3):136-42. Erratum in: J Prev Med Hyg. 2012 Dec;53(4):220. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.


The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.

Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, Chou AH, Chong P, Hsieh SM, Chang SC.

J Microbiol Immunol Infect. 2013 Dec;46(6):448-55. doi: 10.1016/j.jmii.2012.08.002.


A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A.

Clin Vaccine Immunol. 2010 Nov;17(11):1817-9. doi: 10.1128/CVI.00461-09.


Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.

Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, Ince D, Noah DL, Hill H, Bellamy AR; DMID 13-0032 H7N9 Vaccine Study Group..

JAMA. 2014 Oct 8;312(14):1409-19. doi: 10.1001/jama.2014.12854.


Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G.

Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445.


Supplemental Content

Support Center